Martin D, Chinookoswong N, Miller G
Department of Pharmacology, Synergen, Inc., Boulder, Colorado 80301.
Exp Neurol. 1994 Dec;130(2):362-7. doi: 10.1006/exnr.1994.1215.
We assessed the cerebral protective effects of the competitive interleukin-1 antagonist rhIL-1ra in 7-day-old rats that were subjected to brain hypoxia-ischemia by unilateral carotid artery ligation and subsequent exposure to 2 h of 7.5% O2-balanced N2. This procedure leads to atrophy in the cerebral hemisphere ipsilateral to carotid occlusion, with prominent foci of neuronal infarction in the striatum. Systemic administration of 100 mg/kg of rhIL-1ra before and/or after the hypoxic exposure limited the insult. The results indicate that rhIL-1ra has potent neuroprotective properties against morphologic brain injury from hypoxia-ischemia. rhIL-1ra may prove to be clinically useful in protecting against hypoxia-ischemia-related disorders.
我们评估了竞争性白细胞介素-1拮抗剂重组人白细胞介素-1受体拮抗剂(rhIL-1ra)对7日龄大鼠的脑保护作用,这些大鼠通过单侧颈动脉结扎并随后暴露于7.5%氧气-平衡氮气环境2小时而遭受脑缺氧缺血。该操作导致颈动脉闭塞同侧的大脑半球萎缩,纹状体中有明显的神经元梗死灶。在缺氧暴露之前和/或之后全身给予100 mg/kg的rhIL-1ra可减轻损伤。结果表明,rhIL-1ra对缺氧缺血引起的脑形态学损伤具有强大的神经保护特性。rhIL-1ra可能在预防缺氧缺血相关疾病方面具有临床应用价值。